Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

143.72 -1.09 (-0.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

78 79 Next >

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections ↗

September 12, 2024

Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by...

Via Benzinga

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention ↗

September 12, 2024

The company is trying to get ahead of a patent expiration for one of its key HIV prevention drugs.

Via Investor's Business Daily

Topics Intellectual Property

What the Options Market Tells Us About Gilead Sciences ↗

September 12, 2024

Via Benzinga

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

September 12, 2024

From Gilead Sciences, Inc.

Via Business Wire

Biotech Breakout: Stocks for Your Watchlist

September 12, 2024

The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.

Via MarketBeat

Topics ETFs

Peering Into Gilead Sciences's Recent Short Interest ↗

September 06, 2024

Via Benzinga

Unveiling 10 Analyst Insights On Gilead Sciences ↗

September 04, 2024

Via Benzinga

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

September 10, 2024

From Gilead Sciences, Inc.

Via Business Wire

Four Stocks To Watch This Week - Monday, Sept 9 ↗

September 09, 2024

Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels.

Via Talk Markets

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

September 05, 2024

From Gilead Sciences, Inc.

Via Business Wire

Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street ↗

September 03, 2024

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals.

Via Benzinga

Gilead Sciences Options Trading: A Deep Dive into Market Sentiment ↗

September 03, 2024

Via Benzinga

Decoding Gilead Sciences's Options Activity: What's the Big Picture? ↗

August 27, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today ↗

August 22, 2024

Via Benzinga

Biotech And Life Science Sector Update Summer Of 2024 ↗

August 29, 2024

It’s the slowest week of the year, we are at the market top and most earnings reports are good.

Via Talk Markets

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗

August 26, 2024

The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.

Via Investor's Business Daily

Gilead Sciences to Present at Upcoming Investor Conferences

August 21, 2024

From Gilead Sciences, Inc.

Via Business Wire

Biotech Bull Market: 3 Ways To Play It ↗

August 20, 2024

Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.

Via Talk Markets

Topics Economy

Peering Into Gilead Sciences's Recent Short Interest ↗

August 20, 2024

Via Benzinga

Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts ↗

August 15, 2024

Via Benzinga

Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat ↗

August 08, 2024

The company retained its full-year outlook for product sales.

Via Investor's Business Daily

Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs ↗

August 16, 2024

Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs, intensifying its...

Via Benzinga

Topics Lawsuit

FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal ↗

August 15, 2024

FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued...

Via Benzinga

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

August 14, 2024

From Gilead Sciences, Inc.

Via Business Wire

7 Defensive Stocks to Buy as Investors Seek Shelter ↗

August 14, 2024

With the market primed for more jitters, investors should consider battening down the hatches with these defensive stocks.

Via InvestorPlace

3 Stocks Retirees Should Absolutely Love ↗

August 10, 2024

All of these stocks can provide steady income to retired investors.

Via The Motley Fool

Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels ↗

August 09, 2024

Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, and Oncology. Adjusted EPS surged to $2.01, surpassing estimates, supported by...

Via Benzinga

Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday? ↗

August 09, 2024

After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic...

Via Benzinga

Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript ↗

August 08, 2024

GILD earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.